Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
Based out of Boston, Vivek will build on the foundation created by Vaidheesh, and will help build a stronger customer connect and further drive global expansion of the platform
USFDA concludes inspection of Dr. Reddy's Laboratories R&D centre in Bachupally with zero observation
Coupled with Shea Butter, Cocoa Butter, and Mango Butter, the balm provides deep hydration, ensuring lips remain soft, smooth, and well-moisturized throughout the day
Eugia Steriles receives EIR from USFDA for new injectable facility
This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'
Target identification will commence on 17 September 2024, following the timeline provided in the campaign guidelines
GPCB has also asked to submit a bank guarantee of Rs. 2, 00,000 for compliance assurance at the time of revocation and has also ordered to deposit interim environment damage compensation amount
The sANDA was submitted as “Prior Approval Supplement” for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility
Subscribe To Our Newsletter & Stay Updated
